Indolent Systemic Mastocytosis
13
4
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (13)
An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
Angioedema Biomarker Research Study
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002
Treatment of Indolent Systemic Mastocytosis With PA101
Midostaurin in Indolent Systemic Mastocytosis